BR0014615A - Derivado de ácido fosfÈnico que apresenta atividade inibidora contra carboxipeptidase b - Google Patents

Derivado de ácido fosfÈnico que apresenta atividade inibidora contra carboxipeptidase b

Info

Publication number
BR0014615A
BR0014615A BR0014615-3A BR0014615A BR0014615A BR 0014615 A BR0014615 A BR 0014615A BR 0014615 A BR0014615 A BR 0014615A BR 0014615 A BR0014615 A BR 0014615A
Authority
BR
Brazil
Prior art keywords
group
alkyl group
hydrogen atom
activity against
represent
Prior art date
Application number
BR0014615-3A
Other languages
English (en)
Inventor
Kenichi Fushihara
Chika Kikuchi
Tetsuya Matsushima
Kenichi Kanemoto
Eriko Satoh
Takehiro Yamamoto
Kokichi Suzuki
Original Assignee
Meiji Seika Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha filed Critical Meiji Seika Kaisha
Publication of BR0014615A publication Critical patent/BR0014615A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/30Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006Esters of acyclic acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4018Esters of cycloaliphatic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4071Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075Esters with hydroxyalkyl compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/59Hydrogenated pyridine rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533Six-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

"DERIVADO DE áCIDO FOSFÈNICO QUE APRESENTA ATIVIDADE INIBIDORA CONTRA CARBOXIPEPTIDASE B". Caracterizado pelo fato de compreender um composto representado pela Fórmula Geral ( I ) a seguir e um de seus sais farmacologicamente aceitáveis: em que R^ 1^ representa um átomo de hidrogênio, um grupo alquila, um grupo alquila substituído e similares; R^ 2^ e R^ 3^ representam um átomo de hidrogênio, um grupo alquila, um grupo alquila substituído, um grupo alcoxila e similares; X representa -CH~ 2~-, -O- ou -NH-; A representa o seguinte grupo ( II ): [ em que R^ 7^ e R^ 8^ representam um átomo de hidrogênio, um grupo alquila, um grupo acila, um grupo alcoxicarbonila e similares; R^ 9^ e R^ 10^ representam um átomo de hidrogênio, um átomo de halogênio, um grupo hidroxila, um grupo fenila, um grupo alquila e similares ] e similares; e E representa um átomo de hidrogênio e similares, que apresenta atividade inibidora contra carboxipeptidase B e é útil para o tratamento terapêutico e/ou preventivo de uma doença trombótica.
BR0014615-3A 1999-09-14 2000-09-13 Derivado de ácido fosfÈnico que apresenta atividade inibidora contra carboxipeptidase b BR0014615A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP26099399 1999-09-14
JP2000084145 2000-03-24
PCT/JP2000/006248 WO2001019836A1 (fr) 1999-09-14 2000-09-13 Derives d'acides phosphoniques presentant une activite inhibitrice de carboxypeptidase b

Publications (1)

Publication Number Publication Date
BR0014615A true BR0014615A (pt) 2002-06-18

Family

ID=26544854

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014615-3A BR0014615A (pt) 1999-09-14 2000-09-13 Derivado de ácido fosfÈnico que apresenta atividade inibidora contra carboxipeptidase b

Country Status (14)

Country Link
US (2) US6576627B1 (pt)
EP (2) EP1152004B1 (pt)
JP (1) JP3400798B2 (pt)
KR (1) KR100681632B1 (pt)
CN (1) CN1187360C (pt)
AT (1) ATE239741T1 (pt)
AU (1) AU780542B2 (pt)
BR (1) BR0014615A (pt)
CA (1) CA2381801C (pt)
DE (1) DE60002558T2 (pt)
ES (1) ES2202171T3 (pt)
MX (1) MXPA02002671A (pt)
TW (1) TWI223651B (pt)
WO (1) WO2001019836A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
SE0103272D0 (sv) 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
US6713496B2 (en) 2002-01-22 2004-03-30 Pfizer Inc 3-(imidazolyl)-2-alkoxypropanoic acids
JP2005516972A (ja) 2002-01-22 2005-06-09 ファイザー・インク 血栓疾患の治療のためのtafi−a阻害剤として使用される3−(イミダゾリル)−2−アミノプロピオン酸
CA2714873A1 (en) * 2002-03-21 2003-10-02 Schering Aktiengesellschaft Plasma carboxypeptidase b inhibitors
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
AU2003266713A1 (en) * 2002-10-01 2004-05-04 Meiji Seika Kaisha, Ltd. Intermediate for producing carboxypeptidase b inhibitor
US8067187B2 (en) 2005-07-13 2011-11-29 Crossbeta Biosciences B.V. Cross-β structure binding compounds
US8114832B2 (en) 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
US7820323B1 (en) 2006-09-07 2010-10-26 The United States Of America As Represented By The Secretary Of The Army Metal borate synthesis process
US7833660B1 (en) 2006-09-07 2010-11-16 The United States Of America As Represented By The Secretary Of The Army Fluorohaloborate salts, synthesis and use thereof
CA2741783A1 (en) 2008-10-29 2010-05-06 Taisho Pharmaceutical Co., Ltd. Compounds having tafia inhibitory activity
CN103140483B (zh) 2010-07-15 2015-06-24 拜耳知识产权有限责任公司 作为杀虫剂的新杂环化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE212739C (pt)
US4452791A (en) 1982-03-15 1984-06-05 E. R. Squibb & Sons, Inc. Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors
US4560680A (en) 1982-03-15 1985-12-24 E. R. Squibb & Sons, Inc. Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors
US4616005A (en) 1982-06-23 1986-10-07 E. R. Squibb & Sons, Inc. Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
JPS63215686A (ja) * 1987-03-03 1988-09-08 Mitsubishi Kasei Corp アミノエチルホスフイン酸誘導体
US5030732A (en) * 1988-03-03 1991-07-09 Merck & Co., Inc. Aminoethylphosphinic acid derivatives
JP2001515013A (ja) 1997-08-14 2001-09-18 デパートメント オブ ジ アーミー, ユー.エス. ガバメント 網膜病変および脊髄傷害の処置または予防
US6121252A (en) 1998-03-30 2000-09-19 Guilford Pharmaceuticals Inc. Phosphinic acid derivatives
US6444657B1 (en) * 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
AR023819A1 (es) 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
SE9901573D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds

Also Published As

Publication number Publication date
EP1152004A1 (en) 2001-11-07
CA2381801C (en) 2009-12-08
US20030119787A1 (en) 2003-06-26
TWI223651B (en) 2004-11-11
EP1152004B1 (en) 2003-05-07
CN1187360C (zh) 2005-02-02
JP3400798B2 (ja) 2003-04-28
MXPA02002671A (es) 2002-07-30
ATE239741T1 (de) 2003-05-15
DE60002558T2 (de) 2004-04-08
US6576627B1 (en) 2003-06-10
DE60002558D1 (de) 2003-06-12
CN1373766A (zh) 2002-10-09
WO2001019836A1 (fr) 2001-03-22
US6737416B2 (en) 2004-05-18
ES2202171T3 (es) 2004-04-01
EP1152004A4 (en) 2002-01-23
AU780542B2 (en) 2005-03-24
CA2381801A1 (en) 2001-03-22
AU7311200A (en) 2001-04-17
KR20020026268A (ko) 2002-04-06
KR100681632B1 (ko) 2007-02-09
EP1174434A1 (en) 2002-01-23

Similar Documents

Publication Publication Date Title
BR0014615A (pt) Derivado de ácido fosfÈnico que apresenta atividade inibidora contra carboxipeptidase b
NO324249B1 (no) Glykopyranosyloksybenzylbenzenderivater, medisinske sammensetninger inneholdende slike, samt intermediater til fremstilling av derivatene
TW200420542A (en) A compound having TGF β inhibition activity and a medicinal composition containing the same
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
TWI265929B (en) Triazinyl derivatives for inhibiting the production of IL-12
BR9811521A (pt) Composição para tratar ou impedir a glomerulopatia
IT1311922B1 (it) Composti farmaceutici.
BR0113389A (pt) Compostos que inibem a atividade do fator xa
IL136100A0 (en) Biphenylamidine derivatives, prodrugs thereof and pharmaceutical compositions containing the same
DE69623497T2 (de) 1-methylcarbapenem-derivate
NO20060277L (no) Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger
EP1252890A4 (en) MEDICINAL AND PREVENTIVE AGENTS FOR DIGESTIVE DISEASES CONTAINING DIAMINOTRIFLUOROMETHYLPYRIDINE COMPOUNDS
BR0206036A (pt) Derivados de ácido benzóico substituìdos tendo ação de inibição de nf-kb
NO20012443D0 (no) Benzoksazolderivater og legemidler inneholdende disse som aktiv bestanddel
HUP0000966A2 (hu) Izoflavonszármazékok és ilyen vegyületeket hatóanyagként tartalmazó gyógyszerkészítmények
PT998930E (pt) Composto azasteroide para o tratamento da alopecia hirsutismo ou seborreia
AU2001228862A1 (en) Remedies or preventives for liver diseases containing diaminotrifluoromethylpyridine derivatives
HUP0301561A2 (hu) Triazintrion-szulfoxidok alkalmazása kokcidiózis elleni készítmények elżállítására
NO993911L (no) Remedier/Forebygningsmidler for Õndedrettssykdommer
DE60203029D1 (de) Benzopyran Derivate und diese enthaltende Antiallergisches Mittel

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B15Z Prolongation of time limit refused

Free format text: NEGADA A SOLICITACAO DE DEVOLUCAO DE PRAZO UMA VEZ QUE A MESMA NAO FOI APRESENTADA AO INPI NA VIGENCIA DO PRAZO PREVISTO PARA A PRATICA DO ATO, CONFORME DEFINIDO NO ART. 221 DA LPI E NO ART. 2O, PARAGRAFO UNICO, DA RESOLUCAO NO 116/04. A COPIA DO PARECER (DAS RAZOES) PODERA SER SOLICITADA ATRAVES DO FORMULARIO 1.05. (DESTA DATA CORRE O PRAZO DE 60 (SESSENTA) DIAS PARA EVENTUAL RECURSO DO INTERESSADO).

B12F Other appeals [chapter 12.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2440 DE 10/10/2017.